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Phosphoinositide-3 kinases (PI3Ks) generate 3-phosphorylated phosphoinositide lipids
that are implicated in many biological processes in homeostatic states and pathologies
such as cancer, inflammation and autoimmunity. Eight isoforms of PI3K exist in mammals
and among them the class I PI3K, p110γ, and PI3Kδ, and class III Vps34 being the most
expressed and well characterized in immune cells. Following engagement of pathogen
recognition receptors (PRRs), PI3Ks coordinate vital cellular processes of signaling and
vesicular trafficking in innate phagocytes such as macrophages and professional antigen
presenting dendritic cells (DCs). Although previous studies demonstrated the involvement
of PI3K isoforms in innate and adaptive immune cell types, the role of PI3Ks with respect
to DC biology has been enigmatic. Thus, this review, based on studies involving PI3K
isoforms, highlight how the different PI3Ks isoforms could regulate DC functions such as
antigen processing and presentation including PRR responses.
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INTRODUCTION
PI3Ks are activated by diverse signaling pathways including small G proteins of Ras and Rac family,
tyrosine kinases- or G-protein- coupled receptors (1). PI3Ks comprise three class I, II, and III family
of enzymes. Except for class II PI3K (isoforms α, β, δ) which has only catalytic subunits, class
I (isoforms α, β, δ, γ) and class III (Vps34) PI3Ks form heterodimeric molecules, which consist
of the assembly of a catalytic and a regulatory subunit(s) (Figure 1). PI3Ks phosphorylate the
3-hydroxyl group of the inositol ring of three species of phosphatidylinositol (PI) lipid substrates;
namely, PI, PI-4-phosphate PI(4)P, and PI-4,5-bisphosphate PI(4,5)P2. They catalyze the formation
of 3-phosphorylated phosphoinositide lipids, such as phosphoinositol-4,5 biphosphate PI(4,5)P2
into phosphoinositol-3,4,5 triphosphate PI(3,4,5)P3 for class I, and generation of phosphoinositol
triphosphate PI(3)P from phosphoinositol (PI) or phosphoinositol-3,4 bisphosphate PI(3,4)P2
from phosphoinositol phosphate PI(4)P for class II, and finally only the production of
phosphoinositol triphosphate PI(3)P from PI for class III.
PI3Ks are evolutionarily conserved from soil dwelling amoeba, Dictyostelium discoideum
to mammals (2). The evolutionary conservation of PI3K families and its functions from the
Dictyostelium, an archetypical phagocyte, to mammals in generating membrane phospholipids
highlights the importance of these kinases in endocytic and phagocytic processes and their
non-redundant functions in innate phagocytes including dendritic cells (DCs, Figure 2).
Aksoy et al. PI3K in Dendritic Cells
FIGURE 1 | Different classes of PI3Ks. All PI3Ks isoforms (p110 α, β, δ, γ, C2α, C2β, C2γ, Vps34) have 3 to 5 domains: an N terminal domain which can bind the
regulatory p85 proteins, a Ras binding domain, a C2 domain which binds membranes, an helical domain of unknown function and a catalytic subunit with kinase
activity. They associate with a regulatory subunit, p85 isoforms (for p110 α, β, δ), p101, and p87 for p110γ and Vps15 for Vps34. P85 regulatory subunits are encoded
by different genes: PI3KR1 (depending on the promoter will give p85α, p55α, p50β), PI3KR2 (p85β), and PI3KR3 (p55γ). PI3Ks use phospatidylinositol lipids as their
substrates.
THE ROLE OF PI3KS IN DC MEDIATED
HOMEOSTATIC REGULATION OF
INFLAMMATION AND IMMUNITY
PI3K isoforms, particularly class I family of enzymes, have
distinct tissue and cell distribution in mammals. Whereas
PI3Kδ and PI3Kγ are preferentially expressed in immune cells
of hematopoietic origin at high levels, PI3Kα, and PI3Kβ
are ubiquitous and broadly expressed in all somatic cells (4).
However, data from published microarrays suggest differential
expression of PI3Kγ and δ in subset of DCs. PI3Kδ mRNAs
are well expressed in plasmacytoid DCs (pDCs), subset of DCs
Abbreviations: APC, antigen presenting cells; PI3Ks, Phosphoinositide−3
kinases; PRRs, pathogen recognition receptors; DC, dendritic cells;
PI, phosphatidylinositol; PI(4)P, phosphoinositol phosphate; PI(4,5)P2,
phosphoinositol-4,5-bisphosphate; PI(3,4,5)P3, phosphoinositol-3,4,5
triphosphate; PI(3,4)P2, phosphoinositol-3,4 bisphosphate; PI(3)P,
phosphoinositol triphosphate; IFN, interferon; MHCI, major histocompatibilty
class I; pDCs, plasmacytoid DCs; OVA, ovalbumin; MHCII, major
histocompatibility class II.
producing high amount of type I interferon (IFN) following viral
infection, and PI3Kγ mRNA expression was found exclusively
restricted to type 2 DCs or cDC2 (5). These data remain to be
confirmed at the protein level but might imply a preferential role
for PI3Kγ inmajor histocompatibility class II (MHCH II) antigen
presentation as cDC2 are themainDCs subset to present antigens
to CD4+ T cells (6).
Over the last decade, a number of PI3K isoform-selective
gene-targeted mouse models for class I PI3K catalytic and
regulatory subunits and class III PI3K have been generated and
together with the development of isoform specific inhibitors
have greatly advanced the understanding of PI3K signaling in
mammalian biology. Due to the cell type specific expression
of PI3Kγ and PI3Kδ, targeting these isoforms affect innate
and adaptive immune responses (7). Studies using genetic and
pharmacological targeting of PI3Kδ isoform has shown PI3Kδ
is a homeostatic regulator of activation, downstream of Mal-
MyD88-coupled TLR2 and TLR4 signaling pathways in DCs.
PI3Kδ achieves this by dampening pro-inflammatory cytokine
secretion, while supporting production of IL-10 (8). PI3Kγ was
shown to be needed for the development of lung CD11b+DC and
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FIGURE 2 | PI3Ks generate membrane phospholipids important for vesicular trafficking events in DCs. (a) Bacteria, cell debris, and large particles are taken up in
Rab5+ dynamin+ early phagosomes that undergo maturation to generate Rab7+ LAMP1+ late phagosome. Pathogens such as bacteria and yeast can be
internalized into LC3 associated phagosome (LAP) where Rac2 and NOX2 are recruited and are required to generate reactive oxygen species (ROS). (b) During
endocytosis, ligands bound to G protein coupled- and tyrosine kinase-receptors are taken up from the plasma membrane into Rab5+ early endosomes and then
either traffic to Rab7+ LAMP1+ late endosomes or are recycled back to the plasma membrane. (c) During autophagy, a double membrane organelle is generated
from an omegasome (specific ER structure) where Vps34, Vps15, and Beclin1 are recruited. This double membrane organelle will form later the autophagosome by
ingesting cytoplasmic material. Ultimately, all transport vesicles (late phagosome, late endosome, autophagosome) will fuse with the lysosomes for cargo degradation.
PI(4,5)P2 is enriched proximal to the plasma membrane and in lysosomal location. Class I PI3Ks produce PI(3,4,5)P3 from PI(4,5)P2, while class II and III PI3Ks
produce PI(3)P following phagosome enclosure, and PI(3,4,5)P3 is converted into PI(3,4,)P2 by SHIP1 and SHIP2 (3) phosphatases. PI(3)P and PI(3.5)P2 are present
in late endosomes.
CD103+DCs especially by regulation of signaling downstream of
Flt3, whereas it was dispensable for DC development in many
other tissues (9). PI3Kγ deficiency was, in mice, demonstrated
to increase susceptibility to influenza virus infection due to
impaired T cell priming by lung resident DC and delayed
viral clearance owing to the pre-existing DC developmental
deficiency in the lung compartment. In another study, PI3Kγ
deficient mice showed selective reduction in the number of skin
Langerhans cells and in lymph node CD8α−DC (10). Pan PI3K
inhibitors such as wortmannin and LY294002 and deficiency in
the PI3Kδ or p85α regulatory isoform of class I PI3Ks (that
couples to PI3Kα, β or δ isoforms) were found to enhance
TLR4 mediated pro-inflammatory responses by LPS in myeloid
cells including DC and macrophages (8, 11–15). TLR4 activation
triggers Mal-MyD88 signaling originating from the plasma
membrane via phosphoinositol 4,5-bisphosphate [PI(4,5)P2]-
localized TIRAP signaling, which is consecutively followed by
phosphoinositol–binding TRAM mediated endocytic pathway
leading to type I IFNβ production (16, 17). This study has shown
that PI3Kδ mediates the switch between TIRAP-dependent
pro-inflammatory pathway coupled to TLR4 endocytosis and
TIRAP degradation subsequently leading to TRAM-dependent
type I IFNβ and IL-10 secretion (8). This type of homeostatic
control indicates that PI3Kδ signaling pathway is a physiological
regulator of inflammation by dampening endotoxemia and
sepsis.
While PI3Kγ and PI3Kδ roles in TLR mediated pro-
inflammatory reactions has been extensively addressed, their role
in DC antigen presentation and DC-dependent T cell-mediated
immunity in infection models have yet to be examined. Indeed,
a recent study, reporting the diminished ability of WT OT1T
cells to provide help for the p110δ kinase-deficient T cells in
Listeria expressing ovalbumin (OVA) infection model, indicates
a possible role of DCs supporting antigen-specific CD8+ T cell
expansion in a PI3Kδ dependent manner (18). In this study,
WT OT1 cells, injected into p110δD910A hosts, showed reduced
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primary immune responses and proliferation. Likewise in other
studies, the PI3Kδ and p85α regulatory subunit deficient mouse
strains were found to exhibit enhanced resistance to Leishmania
major infection, despite mounting impaired T cell responses and
yet intact or enhanced DC pro-inflammatory cytokine response
(19). Also, DCs lacking SHIP1, the phosphatase converting
PI(3,4,5)P3 into PI(3,4)P2, were able to mature and induce
autoimmunity by promoting CD8+ T cells expansion and INFγ
production in an in vivo model of diabetes (20). In agreement
with this, SHIP1 overexpression led to an inability of DCs to
trigger T cell auto immunity (20) suggesting that PI regulated by
SHIP phosphatases and PI3Ks play a major role in DCs antigen
presentation.
Recently, mice deficient for Class III PI3K or Vps34 in
CD11c+DCs were generated (21). These mice showed a specific
reduction in the number of CD8+DCs, subset of DCs specialized
in MHC class I (MHCI) antigen cross presentation, in the spleen
and were defective at presenting dying cell-associated antigens
to the MHCI antigen cross presentation pathway. The defect
was linked to a reduced expression of Tim4, a phospatidylserine
receptor require for uptake of apoptotic cells, in CD8+DCs
lacking Vps34. In contrast, presentation of antigens by the
classical MHC class I and II pathways was increased andmight be
linked to an overall enhancement of DCs activation at the steady
state in the Vps34-CD11c+DCs deficient mice (21). In addition,
a highly selective and potent class III PI3K inhibitor, SAR405 was
reported to influence vesicle trafficking and autophagy (22) and
it will be of importance to unravel the exact role of Vps34 kinase
and scaffolding functions regulating DC biology.
The PI3Kδ and PI3Kγ isoforms are key targets, being
harnessed in chronic inflammatory and autoimmune conditions
such as asthma, psoriasis rheumatoid arthritis (RA) and systemic
lupus erythematous (SLE), with single or dual inhibitors for both
isoforms being tested in clinical trials (23). In OVA-induced
allergic inflammation models, genetic or pharmacological
targeting of PI3Kδ was reported to reduce inflammatory cell
infiltrates and IL-17 secretion (24), while PI3Kδ deficiency in
mice resulted in suppression of Th2 cell mediated responses
to OVA following immunization with OVA antigen in vivo
(25). Although mice lacking PI3Kγ exhibited reduced levels of
eosinophilic airway inflammation, they did not show significant
differences in serum OVA-specific IgE and IgG1 levels and
CD4/CD8T cell balance (26). However, PI3Kδ deficient animals
display reductions in the levels of eosinophil recruitment and
Th2 cytokine response, indicating that DC-mediated antigen
priming of T cells might be altered under PI3Kδ deficiency, a
topic unaddressed so far (26).
THE ROLE OF PI3Ks IN DC MIGRATION
The activation of class I PI3K downstream of several receptors for
chemo attractants, such as chemokines, complement component
C5a, Nformylmethionyl- leucyl-phenylalanine and sphingosine-
1-phosphate explains the pivotal role of these enzymes in cell
migration (27). Interestingly, the role of class I PI3K-dependent
signaling in migratory responses to chemokines was mainly
explored in leukocytes, neutrophils and to a lesser extent, in
macrophages (28–31). Nevertheless, it is very likely that class I
PI3K signaling, especially PI3Kγ and PI3Kδ, have also crucial
roles in DCs migration, a process necessary for DCs to reach
secondary lymphoid organs to present antigens to T cells, in a
similar way as they act in neutrophils and macrophages. The
major class I PI3K activated downstream chemokine receptors in
neutrophils is considered to be the class IB PI3Kγ, although an
important degree of cooperation, still incompletely understood,
exists between PI3Kγ and PI3Kδ in the control of neutrophil
migration. Thus, early steps of neutrophil migration depend
on PI3Kγ, while late steps of neutrophil long-term migration
requires the cooperative action of PI3Kγ and PI3δ (32).
The central molecular event connecting PI3K activation
with cell migration is the production of PI(3,4,5)P3, which
interacts with proteins containing pleckstrin homology domains
(PH). Proteins containing PH-domains include several master
regulators of cytoskeleton remodeling that are essential for cell
migration. These are the guanine nucleotide exchange factors for
Rac (P-REX1 and 2 and VAVs 1, 2 and3) (33, 34) that regulates F-
actin polymerization and myosin assembly (35). The biosensors,
formed by GFP fusion with typical PH domains, specific for
PI(3,4,5)P3, which allows the visualization of PI(3,4,5)P3 in
cells clearly established that PI(3,4,5)P3 is concentrated to
the leading edge of the cell and this is mandatory for Rac
activation, cytoskeleton rearrangements and finally, orientated
neutrophil migration (36, 37). Indeed, neutrophil migration and
wound repair were enhanced in a zebrafish model where SHIP
phosphatases were depleted (38) but were restored to control
level when cells deficient for SHIP were incubated with PI3Kγ
inhibitor. Whether a similar role of PI3Kγ-mediated distribution
of PI(3,4,5)P3 occurs during DC migration remains unknown.
However, studies involving experimental dextran sodium sulfate
(DSS)-induced colitis reported that genetic or pharmacological
inhibition of PI3Kγ is protective, which may be in part due to
inhibitory effects on inflammatory leukocyte migration.
Investigation of the role of PI3Kγ and PI3Kδ in DC and DC-
like cell lines migration is an important issue, which should be
studied in the future. Significant layers of complexity exist in the
study of class I PI3K, notably PI3Kγ and PI3Kβ, in DCmigration.
One is the diversity of DC populations and their different roles
in the immune response (39), which arise the possibility that the
inhibition of one member of class I PI3K will affect the migratory
and chemotactic abilities of a particular DC subset. Thus, it would
be interesting to investigate if pDC migration is depending on
PI3Kδ, while cDC2 migration depends on PI3Kγ (5). PI3Kγ was
shown to play a key role in DC trafficking and in the activation
of specific immunity since PI3Kγ deficient DCs show inhibited
migration to the lymph nodes (LN) in response to CCR7, which
was correlated with reduced DC numbers in LNs (10). Another
level of complexity is given by the existence of two regulatory
sub-units for the master PI3K kinase involved in immune cell
migration, the PI3Kγ (class IB). Unlike all other class I PI3K,
this enzyme has two regulatory subunits, both of them expressed,
but never studied in DCs. It remains to be investigated if these
two regulatory subunits of PI3Kγ have similar functions in DC
migration, by means of differential coupling to distinct signaling
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receptors. And, as a final level of complexity of the class I PI3K
involvement in DCs migration, it should be underlined that
essential regulators of Rac activity, such as Vav1, 2, 3 and P-
Rex1, 2 are differentially expressed in DC subsets according with
the mRNA expression data (5). Thus, Vav1 and 2 proteins are
expressed mainly in pDCs, Vav3 in type 1 DCs, while type 2 DCs
express P-Rex 1 and 2 (5). This pattern of Rac GEFs expression
suggest that downstream targets of class I PI3K activation might
also contribute to different molecular pathways regulating DC
migration in a subset specific way.
PI3K ROLE IN DC TOLEROGENIC
FUNCTIONS AND THEIR ANTIGEN
PRESENTATION POTENTIAL
Although the exact roles of PI3K isoforms in antigen processing
and presentation in DCs remains unknown, there are indications
that tolerogenic DC functions may rely on PI3K-Akt signaling.
PI3K/Akt/mTOR pathway is central to the regulation of
glycolytic metabolism (40, 41), and equally important in DC
immunometabolic activities and maturation associated increase
of co-stimulatory molecules and MHCII surface expression (42).
Consistent with this, PI3K/Akt axis was shown to be essential
for sustained commitment to glycolysis in TLR activated DCs
(43). Furthermore, the existence of close links between glycolysis-
hypoxia and PI3K-Akt signaling in immune cells indicated
that hypoxic conditions may influence PI3K signaling and thus
impact DC functions involving their migration capacity and their
ability to induce Tregs inDSSmodel of colitis as reported (44, 45).
This has come to attention since a recent work using human
1,25D3-DCs demonstrated that tolerogenic DCs, generated by
1,25(OH)2D3, rely on glucose accessibility and aerobic glycolysis
to maintain their tolerance-inducing properties (46). Indeed,
inhibition of the PI3K/Akt/mTOR pathway was shown to reverse
the tolerogenic function of 1,25(OH)2D3-modulated DCs by
a transcriptional reprogramming of glycolysis associated genes.
Furthermore, pan PI3K inhibitors and rapamycin were found to
hinder tolerogenic DCs function, in part, by partial restoration of
CD4+ T cell proliferation (46).
PI3Kδ and PI3Kγ single and dual isoform selective inhibitors
and mice deficient in p110δ or p110γ do not manifest overt
pathogenic phenotypes, despite exhibiting a wide spectrum of
immunological defects. Nevertheless, patients treated with the
PI3Kδ-selective inhibitor idelalisib (Zydelig) manifest serious
side effects, which results in colitis, diarrhea, neutropenia,
pneumonitis and some level of liver damage (47, 48). This overt
clinical phenotype in humans remarkably coincides with the
occurrence of spontaneous colitis in PI3Kδ deficient mice (49).
These mice progressively develop colitis (49) which depends
on the presence of enteric microbiota for colitis development
in germ free p110δ deficient animals (50, 51). The cellular
and molecular mechanisms for increased colitis susceptibility,
under PI3Kδ deficiency requires careful examination of the host
immune status both in mouse studies and in human trials
(52). PI3Kδ deficiency may increase susceptibility to common
infections due to defects in mounting T cell immunity, not only
owing to the diminished function of PI3Kδ deficient T cells,
but also because of faulty function of DC in peripheral tissues,
enriched in microbiome. A clear dissection between the T cell-
andDC-intrinsic role of PI3Ks inmounting the adaptive immune
response require in the future the generation of tissue-specific
PI3K-deficient mouse strains.
PI3K ROLE IN DC-MEDIATED CANCER
IMMUNITY
PI3K pathway-targeted therapies have been tested in oncology
trials and several pharmaceutical companies have developed
selective PI3K inhibitors to target PI3K pathway in diverse types
of cancer cells. Due to the restricted tissue and cell expression,
PI3Kδ and PI3Kγ are attractive drug targets in hematological
cancers, and a distinguished success of efficacy was reported
with PI3Kδ-selective idelalisib in treating Chronic Lymphocytic
Leukemia (CLL) and non-Hodgkin’s lymphoma, and idelalisib is
now approved for clinic (47, 48, 53).
Evidence from genetic or pharmacological targeting studies
indicate that inhibiting class I PI3K isoforms may be beneficial
in improving cancer immunotherapy (54, 55). In parallel to PI3K
research in oncology, several studies have uncovered exciting
and unexpected roles for PI3K catalytic and regulatory subunits
in cancer immunity, potentially by boosting the efficacy of
PI3K-targeted therapies by adapting the immune compartment
(1). Previously, genetic or pharmacological inhibition of PI3Kδ
reduced tumor burden and metastasis in a range of mouse
cancer models including melanoma, thymoma, lung, and breast
cancer (54). In these models, PI3Kδ inhibition was found to
attenuate Treg function and tumor infiltration and surprisingly
did not alter cytotoxic T cell responses, resulting in enhanced
anti-tumor immunity. Interestingly, one of the common side
effect of checkpoint inhibitors in cancer therapy using PDL1, PD-
1, and CTLA blocking antibodies concerns colitis development
due to inhibition of Treg functions (56, 57). It is plausible
that combined with Treg functions, DC-mediated tolerance
inductionmay be altered in PI3Kδ deficiency in both humans and
mice.
Genetic or pharmacological inhibition of p110γ was reported
to reduce tumor growth and metastasis in melanoma, lung,
pancreatic breast, and colon cancer models. The efficacy of
inhibiting PI3Kγ signaling was suggested to involve myeloid cell
recruitment to the tumor microenvironment through integrin
α4β1 mediated adhesion in response to chemotactic signals.
Therefore, intervention of p110γ signaling appears as an
effective target in reducing tumor-associated inflammation and
subsequent angiogenesis response (58, 59).
Overall based on a number of studies, isoform selective
PI3K inhibition in cancer therapy appears to be efficacious, but
it will be critical in the near future to uncover DC-intrinsic
roles of PI3K isoforms, particularly in the context of antigen
presenting cells (APC) functions, since DC orchestrate immune
responses by activating antitumor immunity. Because PI3K
inhibitors, particularly PI3Kδ inhibitors, have been reported to
boost proinflammatory TLR responses and IL12p70 production,
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it will be interesting to find out whether APC functions
and Th1 inducing capacity of DCs will be affected under
PI3K inhibition. Understanding the role of PI3K inhibition
in both innate and adaptive immune functions of DCs will
indicate if PI3K isoform selective inhibitors may be utilized as
novel “innate” check point inhibitors to boost current cancer
therapies.
CONCLUSION
Overall, the exact role and contribution of PI3K isoforms in
APC function of DC in T cell priming is still enigmatic and
new tools such as tissue-specific PI3K-deficient mouse strains
should be developed in the future. These will allow underpinning
DC-intrinsic roles of PI3K isoforms in antigen presentation
during cancer, auto inflammatory and autoimmune diseases.
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